NewAmsterdam Pharma Company N.V.
NASDAQ:NAMSBiotechnology
+$0.12 today
- Market cap
- $2.37B
- Beta
- 0.08
- P/E (TTM)
- -17.2
- EPS (TTM)
- -$1.76
Volume 1.80M
Average 1.21M
NAMS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
NewAmsterdam Pharma Company N.V.NASDAQ: NAMS
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin dips below year-ago levels
Q2 FY2026 selling, general & admin of $26.89M fell 1.4% year over year, behind the +6.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 14.7% from the prior quarter. Over 3 fiscal years it compounded at +76.0% a year.
Context
- Selling, general & admin amounted to 472.4% of revenue in FY2025, up 317.7 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 10 analysts of $81.04M (-23.8%) for the fiscal year ending Dec 2026, a slowdown from the +50.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $26.89M+14.7% QoQ
- Last fiscal yearDec 2025
- $106.3M+50.9% YoY
- LTMJun 2026
- $102.22M+6.5% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 106.3M USD
- Year-over-year change
- +50.9%
- 4-year CAGR
- +108.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 106.3M | +50.9% |
| FY2024 | 2024-12-31 | 70.45M | +87.2% |
| FY2023 | 2023-12-31 | 37.63M | +92.9% |
| FY2022 | 2022-12-31 | 19.51M | +243.6% |
| FY2021 | 2021-12-31 | 5.68M | — |
Selling, General & Admin vs competitors
How NAMS compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +6.5% is the 7th highest of 9, against a peer median of +17.5%.
- Selling, general & admin amounts to 1435.5% of revenue for NAMS, versus a peer median of 100.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.01B USD | +64.1% | +156.7% | 78.4% | |
| LTM Jun 2026 | $139.03M USD | +19.2% | +2.4% | 3857.6% | |
| LTM Jun 2026 | $102.22M USD | +6.5% | +76.0% | 1435.5% | |
| LTM Sep 2026 | $74.79M USD | +15.8% | -20.9% | — | |
| LTM Jun 2026 | $50.71M USD | -11.8% | +44.2% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | $36.57M USD | +38.0% | — | 38.0% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $28.7M USD | +27.8% | +43.3% | 278.2% |
| LTM Mar 2026 | $18.46M USD | -7.7% | +13.7% | — | |
| FY2025 | A$5.48M AUD | +15.1% | -0.2% | 100.8% | |
| Peer median (excluding NAMS) | — | +17.5% | +13.7% | 100.8% | |
Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 102.69M | 14.09M | 45.56M | 22.5M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 59K |
| Gross Profit | 0 | 102.69M | 14.09M | 45.56M | 22.44M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 99.7% |
| Research & Development | 28.97M | 86.74M | 159.42M | 151.41M | 141.83M |
| Selling, General & Admin | 5.68M | 19.51M | 37.63M | 70.45M | 106.3M |
| Operating Expenses | 34.98M | 106.25M | 197.06M | 221.85M | 248.13M |
| Depreciation & Amortization | 5K | 9K | 49K | 113K | 220K |
| EBITDA | (41.37M) | (22.34M) | (176.86M) | (241.49M) | (242.33M) |
| EBITDA Margin | — | -21.8% | -1255.2% | -530.0% | -1076.9% |
| Operating Income | (34.98M) | (3.56M) | (182.97M) | (176.29M) | (225.68M) |
| Operating Margin | — | -3.5% | -1298.6% | -386.9% | -1002.9% |
| Interest Income | 0 | 0 | 10.22M | 16.88M | 27.59M |
| Interest Expense | 411K | 287K | 6.8M | 0 | 0 |
| Other Income / Expenses | (6.81M) | (19.08M) | 6.06M | (65.31M) | 21.86M |
| Income Before Tax | (41.79M) | (22.63M) | (176.91M) | (241.6M) | (203.82M) |
| Pre-Tax Margin | — | -22.0% | -1255.6% | -530.3% | -905.7% |
| Income Tax Expense | 0 | 0 | 27K | (1K) | 0 |
| Net Income | (41.79M) | (22.63M) | (176.94M) | (241.6M) | (203.82M) |
| Net Margin | — | -22.0% | -1255.8% | -530.3% | -905.7% |
| EPS (Basic) | (3.34) | (1.19) | (2.15) | (2.56) | (1.75) |
| EPS (Diluted) | (3.34) | (1.19) | (2.15) | (2.56) | (1.75) |
| Weighted Avg Shares | 17.75M | 18.97M | 82.16M | 94.36M | 114.4M |
| Weighted Avg Shares (Diluted) | 17.75M | 18.97M | 82.16M | 94.36M | 114.4M |
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
Intrinsic Alpha fair value
Locked
Current Price
$19.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.